PTH Compounds with Low Peak-To-Trough Ratios

A method of treating a human patient having hypoparathyroidism comprising subcutaneously administering to the patient a PTH compound, wherein the pharmacokinetic profile of the PTH compound exhibits a peak to trough ratio of less than 4 within one administration interval, wherein the PTH compound is a compound of formula (Ia) or (Ib) or a pharmaceutically acceptable salt thereof

• wherein
• -D is a PTH moiety;
• -L1- is a reversible prodrug linker moiety connected to the PTH moiety -D through a functional group of PTH;
• -L2- is a single chemical bond or a spacer moiety;
• —Z is a water-soluble carrier moiety;
• x is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16;
• and
• y is an integer selected from the group consisting of 1, 2, 3, 4 and 5.